Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRONewsfile Corp • 05/28/22
EQUITY ALERT: Rosen Law Firm Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPROBusiness Wire • 05/27/22
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/16/22
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 05/16/22
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022GlobeNewsWire • 05/09/22
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage PipelineGlobeNewsWire • 05/03/22
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPROPRNewsWire • 04/25/22
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious DiseasesGlobeNewsWire • 04/21/22
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of MedicineGlobeNewsWire • 04/06/22
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/01/22
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/31/22
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business UpdateGlobeNewsWire • 03/31/22
Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?Zacks Investment Research • 03/29/22
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022GlobeNewsWire • 03/17/22
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the HospitalGlobeNewsWire • 02/16/22
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric PatientsGlobeNewsWire • 01/19/22
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including PyelonephritisGlobeNewsWire • 01/03/22